Ionis Pharmaceuticals IONS Effective Income Tax Rate Reconciliation Tax Credits Research
Effective Income Tax Rate Reconciliation Tax Credits Research at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch.
The official record: Ionis Pharmaceuticals’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ionis Pharmaceuticals's effective income tax rate reconciliation tax credits research.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ionis Pharmaceuticals's effective income tax rate reconciliation tax credits research?
- Ionis Pharmaceuticals (IONS) reported effective income tax rate reconciliation tax credits research of -4.7% in Q4 2025.
- What does effective income tax rate reconciliation tax credits research mean?
- The percentage reduction in the effective tax rate attributed to research and development tax credits.
- How do you interpret effective income tax rate reconciliation tax credits research?
- An increase indicates that R&D tax credits are becoming a more significant factor in reducing the company's effective tax rate.
- How does effective income tax rate reconciliation tax credits research compare across companies?
- Standard metric for comparing the tax-efficiency of R&D-heavy companies across the industry.